Hypertension in end-stage renal disease: Transplantation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375589" target="_blank" >RIV/00216208:11130/18:10375589 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/18:10375589 RIV/00064203:_____/18:10375589

Výsledek na webu

<a href="https://doi.org/10.1007/978-3-319-31107-4_49" target="_blank" >https://doi.org/10.1007/978-3-319-31107-4_49</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-319-31107-4_49" target="_blank" >10.1007/978-3-319-31107-4_49</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hypertension in end-stage renal disease: Transplantation

Popis výsledku v původním jazyce

Hypertension in children after renal transplantation is an important risk factor not only for graft loss but also for cardiovascular morbidity and mortality. The prevalence of posttransplant HTN ranges between 60% and 90%. The etiology of posttransplant HTN is multifactorial - chronic native kidney disease, immunosuppressive therapy, and chronic allograft dysfunction are the most common causes. Casual blood pressure (BP) should be measured at each outpatient visit; however, ambulatory blood pressure monitoring (ABPM) is the best method for BP evaluation in children after renal transplantation, as it often discloses especially nighttime HTN; given this, it should be regularly performed in each transplanted child. All classes of antihypertensive drugs are used in the treatment of posttransplant HTN because it has never been proven that one class would be better than another. The most commonly used antihypertensives are calcium channel blockers. The target BP for transplant children is still a matter of debate; it is recommended to target the same BP as for healthy children, i.e., 90th percentile. Control of HTN in transplanted children still remains poor - only 20-50% of treated children have normal BP. There is a great potential for improvement of antihypertensive treatment that could potentially result in improvement of both graft and patient survival in children after renal transplantation.

Název v anglickém jazyce

Hypertension in end-stage renal disease: Transplantation

Popis výsledku anglicky

Hypertension in children after renal transplantation is an important risk factor not only for graft loss but also for cardiovascular morbidity and mortality. The prevalence of posttransplant HTN ranges between 60% and 90%. The etiology of posttransplant HTN is multifactorial - chronic native kidney disease, immunosuppressive therapy, and chronic allograft dysfunction are the most common causes. Casual blood pressure (BP) should be measured at each outpatient visit; however, ambulatory blood pressure monitoring (ABPM) is the best method for BP evaluation in children after renal transplantation, as it often discloses especially nighttime HTN; given this, it should be regularly performed in each transplanted child. All classes of antihypertensive drugs are used in the treatment of posttransplant HTN because it has never been proven that one class would be better than another. The most commonly used antihypertensives are calcium channel blockers. The target BP for transplant children is still a matter of debate; it is recommended to target the same BP as for healthy children, i.e., 90th percentile. Control of HTN in transplanted children still remains poor - only 20-50% of treated children have normal BP. There is a great potential for improvement of antihypertensive treatment that could potentially result in improvement of both graft and patient survival in children after renal transplantation.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Pediatric Hypertension

ISBN

978-3-319-31106-7

Počet stran výsledku

14

Strana od-do

487-500

Počet stran knihy

881

Název nakladatele

Springer International Publishing

Místo vydání

Cham

Kód UT WoS kapitoly

—